The risk of recurrent IgA nephropathy in a steroid‐free protocol and other modifying immunosuppression | doi.page

0 citations0 references

The risk of recurrent IgA nephropathy in a steroid‐free protocol and other modifying immunosuppression

Clinical Transplantation2014Vol. 28(8), pp. 845–854

Citations Over TimeTop 10% of 2014 papers

Jon R. Von Visger, Yusuf Günay, Kenneth A. Andreoni, Udayan Bhatt, Uday Nori, Todd E. Pesavento, Elmahdi Elkhammas, Holli Winters, Tibor Nádasdy, Neeraj Singh

Abstract

Recurrent glomerulonephritis is an important cause of kidney allograft failure. The effect of immunosuppression on recurrent IgA nephropathy (IgAN) is unclear. We analyzed the impact of steroids and other immunosuppression on the risk of recurrent IgAN post-kidney transplantation. Between June 1989 and November 2008, 3311 kidney transplants were performed at our center. IgAN was the primary disease in 124 patients; of these, 75 (60.5%) patients received steroid-based immunosuppression (15 undergoing late steroid withdrawal), and 49 (39.5%) were maintained on steroid-free immunosuppression. Recurrent IgAN was diagnosed in 27 of 124 (22%) patients in clinically indicated kidney allograft biopsies over a median follow-up of 6.86 ± 5.4 yr. On cox proportional hazards model multivariate analysis, the hazard risk (HR) of IgAN recurrence was significantly higher in patients managed with steroid-free (HR 8.59: 3.03, 24.38, p < 0.001) and sirolimus-based (HR = 3.00:1.16, 7.75, p = 0.024) immunosuppression without antilymphocyte globulin induction (HR = 4.5: 1.77, 11.73, p = 0.002). Mycophenolate use was associated with a lower risk (HR = 0.42: 0.19, 0.95, p = 0.036), whereas cyclosporine did not have a significant impact on the risk of IgAN recurrence (p = 0.61). These results warrant future prospective studies regarding the role of steroids and other immunosuppression drugs in reducing recurrence of IgAN and other glomerulonephritis post-transplant.

Citations Over TimeTop 10% of 2014 papers

Abstract

Related Papers